SLS-012

SLS-012 is a Captisol-enabled formulation of acetaminophen (paracetamol) developed by Seelos Therapeutics under a license from Ligand Pharmaceuticals. The product utilizes Ligand's proprietary Captisol technology—a chemically modified sulfobutylether β-cyclodextrin—to enhance the solubility and stability of acetaminophen. This formulation is intended for the treatment of pain and fever, particularly in settings where an injectable or rapid-onset delivery is advantageous, such as post-operative pain management. While acetaminophen's exact mechanism is complex, it is generally understood to inhibit cyclooxygenase (COX) enzymes in the central nervous system and modulate descending pain pathways.

Other names

Captisol-enabled acetaminophenCaptisol-enabled paracetamol